UroGen Pharma Stock Income Statements

UroGen Pharma Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

UroGen Pharma Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2017-12-31

revenue	24,215,000	20,254,000	24,565,000	25,204,000	21,848,000	18,781,000	23,530,000	20,852,000	21,139,000	17,192,000	18,092,000	16,097,000	16,604,000	13,564,000	16,174,000	11,351,000	13,032,000
yoy	10.83%	7.84%	4.40%	20.87%	3.35%	9.24%	30.06%	29.54%	27.31%	26.75%	11.86%	41.81%	27.41%
qoq	19.56%	-17.55%	-2.54%	15.36%	16.33%	-20.18%	12.84%	-1.36%	22.96%	-4.97%	12.39%	-3.05%	22.41%	-16.14%	42.49%	-12.90%
cost of revenue	3,550,000	2,330,000	2,471,000	2,453,000	2,229,000	1,728,000	2,286,000	2,367,000	2,443,000	2,265,000	2,263,000	2,020,000	1,846,000	1,525,000	1,589,000	1,244,000	1,427,000
gross profit	20,665,000	17,924,000	22,094,000	22,751,000	19,619,000	17,053,000	21,244,000	18,485,000	18,696,000	14,927,000	15,829,000	14,077,000	14,758,000	12,039,000	14,585,000	10,107,000	11,605,000	6,588,000	7,314,000	3,152,000	324,000				18,000
yoy	5.33%	5.11%	4.00%	23.08%	4.94%	14.24%	34.21%	31.31%	26.68%	23.99%	8.53%	39.28%	27.17%	82.74%	99.41%	220.65%	3481.79%				1700.00%
qoq	15.29%	-18.87%	-2.89%	15.96%	15.05%	-19.73%	14.93%	-1.13%	25.25%	-5.70%	12.45%	-4.61%	22.58%	-17.46%	44.31%	-12.91%	76.15%	-9.93%	132.04%	872.84%
gross margin %	85.34%	88.50%	89.94%	90.27%	89.80%	90.80%	90.28%	88.65%	88.44%	86.83%	87.49%	87.45%	88.88%	88.76%	90.18%	89.04%	89.05%
operating expenses:
research and development expenses	18,914,000	19,871,000	14,894,000	11,355,000	15,402,000	15,494,000	11,302,000	10,230,000	11,584,000	12,498,000	14,477,000	13,093,000	12,640,000					10,513,000	12,405,000	10,211,000	8,106,000	16,588,000	20,094,000	9,481,000	9,996,000	9,726,000
selling, general and administrative expenses	43,199,000	34,967,000	34,858,000	28,941,000	30,056,000	27,299,000	24,551,000	21,755,000	22,494,000	24,474,000	21,634,000	19,071,000	20,833,000					22,189,000	22,163,000	22,065,000	24,018,000	21,973,000
operating income	-41,448,000	-36,914,000	-27,658,000	-17,545,000	-25,839,000	-25,740,000	-14,609,000	-13,500,000	-15,382,000	-22,045,000	-20,282,000	-18,087,000	-18,715,000	-21,957,000	-19,915,000	-23,440,000	-22,823,000	-26,114,000	-27,254,000	-29,124,000	-31,800,000	-38,561,000	-39,839,000	-23,453,000	-23,753,000	-22,433,000
yoy	60.41%	43.41%	89.32%	29.96%	67.98%	16.76%	-27.97%	-25.36%	-17.81%	0.40%	1.84%	-22.84%	-18.00%	-15.92%	-26.93%	-19.52%	-28.23%	-32.28%	-31.59%	24.18%	33.88%	71.89%
qoq	12.28%	33.47%	57.64%	-32.10%	0.38%	76.19%	8.21%	-12.24%	-30.22%	8.69%	12.14%	-3.36%	-14.77%	10.25%	-15.04%	2.70%	-12.60%	-4.18%	-6.42%	-8.42%	-17.53%	-3.21%	69.87%	-1.26%	5.88%
operating margin %	-171.17%	-182.26%	-112.59%	-69.61%	-118.27%	-137.05%	-62.09%	-64.74%	-72.77%	-128.23%	-112.10%	-112.36%	-112.71%	-161.88%	-123.13%	-206.50%	-175.13%
financing on prepaid forward obligation	-4,644,000	-4,583,000	-6,063,000	-5,915,000	-5,773,000	-5,660,000	-5,505,000	-5,479,000	-5,344,000	-5,224,000	-5,081,000	-4,819,000	-5,833,000	-5,826,000	-7,343,000	-6,828,000	-3,120,000
interest expense on long-term debt	-4,132,000	-4,068,000	-3,892,000	-2,721,000	-3,461,000	-2,447,000	-3,586,000	-3,815,000	-3,761,000	-3,553,000	-3,223,000	-2,694,000	-2,239,000	-282,000
interest and other income	1,299,000	2,114,000	2,750,000	2,599,000	1,708,000	1,615,000	1,538,000	906,000	405,000	630,000	406,000	478,000	128,000		-57,000	57,000	33,000	179,000	102,000	308,000	451,000	768,000	866,500	1,201,000
income before income taxes	-48,925,000	-43,451,000	-34,863,000	-23,582,000	-33,365,000	-32,232,000	-22,162,000	-21,888,000	-24,082,000	-30,192,000	-28,180,000	-25,122,000	-26,659,000	-28,067,000	-27,315,000	-30,211,000	-25,910,000
income tax expense	-1,015,000	-392,000	-2,649,000	-91,000	-38,000	-54,000	-3,854,000	9,000	-54,000	-21,000	-689,000	-709,000	-32,000	-325,000	1,137,000		312,000
net income	-49,940,000	-43,843,000	-37,512,000	-23,673,000	-33,403,000	-32,286,000	-26,016,000	-21,879,000	-24,136,000	-30,213,000	-28,869,000	-25,831,000	-26,691,000	-28,392,000	-28,452,000	-30,211,000	-26,222,000	-25,935,000	-30,526,000	-28,816,000	-31,349,000	-37,793,000	-38,973,000	-22,252,000	-22,477,000	-21,444,000
yoy	49.51%	35.80%	44.19%	8.20%	38.39%	6.86%	-9.88%	-15.30%	-9.57%	6.41%	1.47%	-14.50%	1.79%	9.47%	-6.79%	4.84%	-16.35%	-31.38%	-21.67%	29.50%	39.47%	76.24%
qoq	13.91%	16.88%	58.46%	-29.13%	3.46%	24.10%	18.91%	-9.35%	-20.11%	4.66%	11.76%	-3.22%	-5.99%	-0.21%	-5.82%	15.21%	1.11%	-15.04%	5.93%	-8.08%	-17.05%	-3.03%	75.14%	-1.00%	4.82%
net income margin %	-206.24%	-216.47%	-152.71%	-93.93%	-152.89%	-171.91%	-110.57%	-104.93%	-114.18%	-175.74%	-159.57%	-160.47%	-160.75%	-209.32%	-175.91%	-266.15%	-201.21%
statements of comprehensive loss
other comprehensive loss
unrealized income on investments	-8,000
comprehensive loss	-49,948,000	-43,885,000	-37,692,000	-23,406,000	-33,397,000	-32,335,000	-25,870,000	-21,859,000	-24,245,000	-30,151,000	-28,821,000	-25,930,000	-26,678,000	-28,436,000	-28,481,000	-30,252,000	-26,320,000	-26,063,000	-30,747,000	-29,084,000	-30,900,000	-37,758,000	-39,000,000	-22,230,000	-22,196,000
net income per ordinary share - basic and diluted	-1,050	-920	-600	-550	-910	-970	-660	-680	-1,030	-1,300	-1,250	-1,130	-1,180
weighted-average number of shares outstanding used in computation of basic and diluted loss per ordinary share	47,739,816,000	47,422,119,000	42,876,737,000	43,100,237,000	36,821,915,000	33,379,786,000	28,834,303,000	32,298,182,000	23,462,016,000	23,279,951,000	22,806,812,000	22,798,263,000	22,703,572,000	22,631,509,000	22,347,481,000	22,380,598,000	22,331,119,000	22,242,375,000	21,780,826,000	22,058,343,000	21,753,001,000	21,158,161,000	20,528,727,000	20,916,780,000	20,833,671,000	19,340,082,000
unrealized loss on investments		-42,000
other comprehensive income
unrealized gain on investments			-180,000	267,000	6,000	-49,000	146,000	20,000	-109,000	62,000			13,000
other comprehensive
unrealized (loss) on investments											48,000	-99,000
operating expense:
research and development expense														12,696,000	8,640,000	11,923,000	12,124,000
selling, general and administrative expense														21,300,000	16,529,250	21,624,000	22,304,000
other income														-2,000
unrealized gain on marketable securities														-44,000	-66,750	-41,000	-98,000	-128,000	-221,000	-268,000	449,000	35,000	-27,000	22,000	281,000
net income per ordinary share basic and diluted														-1,250	-922.5	-1,350	-1,170	-1,170	-1,130	-1,310	-1,440	1,790	-812.5	-1,060	-1,080
revenues																		7,485,000	7,966,000	3,461,000	372,000				18,000
cost of revenues																		897,000	652,000	309,000	48,000
other comprehensive income:
general and administrative expenses																							19,745,000	13,972,000	13,775,000	12,707,000
realized loss on sale of short-term investment
interest and other income (expenses)																									1,276,000
finance income																										-989,000
loss per ordinary share basic and diluted																										1,110

We provide you with 20 years income statements for UroGen Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of UroGen Pharma stock. Explore the full financial landscape of UroGen Pharma stock with our expertly curated income statements.

The information provided in this report about UroGen Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.